Otsuka

Otsuka Enters into a WW License Agreement with Sunovion and Sumitomo Dainippon to Develop and Commercialize Neuropsychiatric Candidates

Shots: Sunovion to receive $270M up front, $620M as development milestone for 4 candidates & is also eligible to receive sales milestone. Sunovion & Otsuka will share profits & expenses for clinical studies, applications for approval, & commercialization in each licensed territories Otsuka gets the rights from Sunovion to jointly develop & commercialize 4 compounds …

Otsuka Enters into a WW License Agreement with Sunovion and Sumitomo Dainippon to Develop and Commercialize Neuropsychiatric Candidates Read More »

Otsuka, Click trial digital depression therapy with Google

Otsuka and Click Therapeutics are working with Verily, the healthcare subsidiary of Google owners Alphabet, on a fully remote clinical trial testing a digital therapy as an add-on in adults with severe depression. Otsuka is on a mission to develop digital technology to treat mental illness and broke new ground by marketed Abilify Mycite (aripiprazole) …

Otsuka, Click trial digital depression therapy with Google Read More »

Former CEO of Proteus reflects on the dramatic fall of ‘digital pill’ unicorn

The US healthcare system’s focus on activity rather than value for money was behind the demise of Proteus Digital Health and its “digital pill”, which measured whether schizophrenia patients took their meds, according to the company’s former CEO. At the Frontiers Health conference Andrew Thompson spoke to pharmaphorum’s web editor Catherine Longworth about lessons that …

Former CEO of Proteus reflects on the dramatic fall of ‘digital pill’ unicorn Read More »

Health in 2 Point 00, Episode 147 | The Most Confusing Episode So Far

With 3 consecutive days of $100M in funding, here is the most confusing (or rather the most confused we have been) Episode 147 of Health in 2 Point 00. Jess asks me about Verily partnering with Swiss Re to get into the stop-loss insurance game, Prescryptive Health raising a $26M Series A for their maybe …

Health in 2 Point 00, Episode 147 | The Most Confusing Episode So Far Read More »

Insights+: The US FDA New Drug Approvals in July 2020

The US FDA has approved multiple NDAs and BLAs in July 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 59 novel products so far in 2020, including 8 in July 2020. Additionally, …

Insights+: The US FDA New Drug Approvals in July 2020 Read More »

Otsuka Inqovi (decitabine and cedazuridine) Received the US FDA’s Approval to MDS and CMML

Shots: The approval was based on P-III trial from the ASCERTAIN study supporting P-I and P-II clinical studies which evaluated the safety and efficacy including decitabine exposure equivalence in oral Inqovi vs intravenous decitabine Otsuka a subsidiary of Astex Pharmaceuticals with its partner Taiho Pharmaceutical and North American reported the approval Inqovi is a novel …

Otsuka Inqovi (decitabine and cedazuridine) Received the US FDA’s Approval to MDS and CMML Read More »